Evidence map›Paper›PMID 23100460›Full record

ReviewNicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco2013

Nicotine reduction: strategic research plan.

Dorothy K Hatsukami, Neal L Benowitz, Eric Donny, Jack Henningfield, Mitch Zeller

Abstract readReview
In one paragraph

Review in Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Regulatory Approaches and Implementation of Minimally Addictive Combusted Products.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2022
    Pooled it
  2. Age Moderates Smokers' Subjective Response to Very-Low Nicotine Content Cigarettes: Evidence from a Randomized Controlled Trial.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2019
    Trial
  3. Trial
  4. Trial
  5. Trial
  6. Effects of 6-Week Use of Reduced-Nicotine Content Cigarettes in Smokers With and Without Elevated Depressive Symptoms.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2017
    Trial
  7. Smoking Topography Characteristics of Very Low Nicotine Content Cigarettes, With and Without Nicotine Replacement, in Smokers With Schizophrenia and Controls.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2016
    Trial
  8. Trial
  9. Nicotine Dependence, Nicotine Metabolism, and the Extent of Compensation in Response to Reduced Nicotine Content Cigarettes.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2015
    Trial
  10. Cognitive effects of very low nicotine content cigarettes, with and without nicotine replacement, in smokers with schizophrenia and controls.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2015
    Trial
  11. Trial
  12. Article
  13. Article
  14. Applying the Population Health Standard to the Regulation of Electronic Nicotine Delivery Systems.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2021
    Review
  15. Article
  16. Article
  17. Pharmacokinetic Profile of Spectrum Reduced Nicotine Cigarettes.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2020
    Article
  18. Article
  19. The Effect of Price on the Consumption of Reduced Nicotine Cigarettes.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2019
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Dorothy K HatsukamiDepartment of Psychiatry, University of Minnesota, Minneapolis, MN 55414, USA. hatsu001@umn.edu
Neal L Benowitz
Eric Donny
Jack Henningfield
Mitch Zeller

Funding

VERY LOW NICOTINE CIGARETTES IN SMOKERS WITH SCHIZOPHRENIAU54DA031659 · NIDA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI COLBY, SUZANNE M · 2011 to 2022
$64.7M
Innovative Interventions for Smoking CessationR01DA025598 · NIDA · UNIVERSITY OF MINNESOTA · PI HATSUKAMI, DOROTHY K · 2009 to 2010
$924k
NIDA NIH HHS DA025598NIDA NIH HHS DA031659NIDA NIH HHS U54 DA031659PHS HHS HHSN26120100438P
6 · The paper itself

Abstract

backgroundReducing nicotine content in cigarettes and other combustible products to levels that are not reinforcing or addictive has the potential to substantially reduce tobacco-related morbidity and mortality. The authority to reduce nicotine levels as a regulatory measure is provided in the U.S. Family Smoking Prevention and Tobacco Control Act and is consistent with the general regulatory powers envisioned under the relevant articles of the World Health Organization's Framework Convention on Tobacco Control. Many experts have considered reducing nicotine in cigarettes to be a feasible national policy approach, but more research is necessary. PURPOSE: This article describes proceedings from a conference that had the goals of identifying specific research gaps, describing methods and measures to consider for addressing these gaps, and considering ways to foster collaboration. RESULTS AND

conclusionIdentified research gaps included determining the dose of nicotine that would be optimal for reducing and extinguishing cigarette use, examining approaches for reducing nicotine levels in the general and special populations of smokers, understanding how constituents other than nicotine may contribute to the reinforcing effects of tobacco, and identifying unintended consequences to determine ways to mitigate them. Methods that can be used ranged from brain imaging to large human clinical trials. The development and availability of valid biomarkers of exposure and effect are important. Infrastructures to facilitate collaboration need to be established.

Indexed as

Smoking PreventionAnimalsBiomarkersHumansNicotineRacial GroupsResearchSmoking CessationTobacco ProductsUnited StatesBiomarkersNicotine

Identifiers

PMID23100460
PMCPMC3646645

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.